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Available online 30 November 2015Commercializedproducts containing live lactic acid bacteria (LAB) are available for the purpose ofmodifying gas-
trointestinal function. In contrast, the impact of sterilized LAB, especially rod-shaped LAB, on intestinal regulation
is not fully understood. Here, we examined the beneﬁcial effects of sterilized Lactobacillus gasseri CP2305
(CP2305) as a “paraprobiotic” on gastrointestinal function in a double-blind, placebo-controlled trial. Subjects
(n = 39) were healthy individuals who had a tendency toward constipation (n= 20) or frequent bowel move-
ments (n = 19). They included both genders (15 males and 24 females) and were 20–70 years of age (mean
44.4 ± 12.4 years). Subjects with constipation or frequent bowel movements were randomly divided into two
groups, and they ingested either an artiﬁcially acidiﬁed milk-based placebo beverage or a heat-inactivated
CP2305 fermented milk (FM)-based beverage for 3 weeks. Subjects kept a stool diary to record the frequency
of bowel movements, the feeling after defecation and the fecal conditions. Fresh fecal samples were collected
to evaluate the fecal characteristics and to analyze the fecal metabolites and the composition of intestinal micro-
biota. The stool characteristics, including the subjective and objective Bristol stool scale scores, output, and color
tone, were improved in the heat-inactivated CP2305 FM-based beverage group (CP2305 group), especially in
subjects who had a tendency toward constipation. Analyses of the fecal samples showed that the concentrations
of short-chain fatty acids (SCFAs)were signiﬁcantly increased in the CP2305 group. The population of Clostridium
cluster IVwas signiﬁcantly increased in theCP2305 group. The heat-inactivatedCP2305 FMhad a beneﬁcial effect
on the regulation of intestinal function. Improvement was observed chieﬂy in subjects that had a tendency to-
ward constipation. These results suggest that heat-inactivated CP2305 functions as a “paraprobiotic”.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The gut is the largest immune and endocrine organ of the human
body (Kim, Park, & Kim, 2014; Rehfeld, 2012). It has been suggested
that modiﬁcations of its function by ingesting certain types of intra-
intestinal stimulators, such as ingested LAB, may occur through the sen-
sory system of the gut. These possible functional alterations may lead to
changes in intraluminal conditions andmay reﬂect changes in the com-
position of intestinal microbiota, as in a cause-and-effect phenomenon.
These alterations may affect various biological functions of the entire
body through the autonomous nervous system, the endocrine system
and the immune system (Sampson & Mazmanian, 2015). Orally ad-
ministered bacterial cells with speciﬁc traits can be considered activeara).
. This is an open access article underintra-gastrointestinal working materials and act through the direct
modulation of gut function or even through whole-body function
via “brain–gut interactions” (Saulnier et al., 2013). Recent studies
have reported that the intestinal microbiota even play roles in the
regulation of mood, anxiety, depression, pain and cognition through
the changes in gut function (Cryan & Dinan, 2012; Foster & McVey
Neufeld, 2013; Yano et al., 2015).
Fermentedmilk (FM) and foods containing living lactic acid bacteria
(LAB) as probiotics are commercially available formodifying the gastro-
intestinal environment. Although “probiotics” as a technical term was
deﬁned originally by Fuller (1989), this term has been redeﬁned several
times and is now deﬁned as “live microorganisms which, when admin-
istered in adequate amounts, confer a health beneﬁt on the host” (FAO,
2002). Previous studies have suggested that the effects of probiotics
could be explained, at least in part, as the competition of the orally ad-
ministered beneﬁcial bacterial strains (probiotics) with pathogenicthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline characteristics of the study groups.
Placebo CP2305
All Constipation Frequent bowel movements Constipation Frequent bowel movements
n 39 10 10 10 9
(Male/Female) (15/24) (3/7) (5/5) (3/7) (4/5)
Age 44.36 ± 12.40 45.30 ± 11.95 44.70 ± 10.47 37.80 ± 12.79 50.22 ± 13.00
Height (cm) 162.61 ± 7.30 162.80 ± 6.45 164.94 ± 8.31 161.83 ± 7.06 160.68 ± 7.79
Weight (kg) 59.67 ± 10.62 61.83 ± 11.00 58.44 ± 8.73 56.70 ± 11.35 61.96 ± 12.01
Body fat (%) 28.14 ± 7.96 29.45 ± 10.15 24.89 ± 5.41 28.45 ± 8.42 29.93 ± 7.30
BMI (kg/m2) 22.51 ± 3.43 23.34 ± 4.00 21.39 ± 2.01 21.59 ± 3.77 23.87 ± 3.45
All values are the means ± SD (standard deviations).
BMI: body mass index.
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(Shimizu et al., 2013).
Wehave focused on the effects of heat-inactivated LAB on gastrointes-
tinal functions. Several studies have revealed that the beneﬁcial effects of
probiotics can be obtained from the administration of dead bacterial cells.
For example, heat-inactivated Enterococcus faecalis EC-12 (EC-12), a
spherical LAB, exerts a signiﬁcant regulatory function in the gut (Terada,
Bukawa, Kan, &Mitsuoka, 2004). The same strain in a sterilized form reg-
ulated gut motility in an experiment with piglets (Tsukahara, Tsukahara,
Bukawa, Kan, & Ushida, 2005). These ﬁndings explain the direct action of
heat-inactivated LAB cells in the modiﬁcation of gut function. Taverniti
and Guglielmetti (2011) deﬁned the technical term “paraprobiotics” as
“non-viable microbial cells (intact or broken) or crude cell extracts
(i.e., with complex chemical composition), which, when administered
(orally or topically) in adequate amounts, confer a beneﬁt on the
human or animal consumer”. Paraprobiotics such as sterilized EC-12 are
already applied commercially for human and animal use. Paraprobiotics
have several attractive advantages for industrial use (Adams, 2010).
First, live bacteria, includingprobiotics,might develop opportunistic path-
ogenicity, especially in cases of use by the elderly (Oggioni, Pozzi,
Valensin, Galieni, & Bigazzi, 1998; Rautio et al., 1999; Salminen et al.,
1998). However, the infection risk would be minimized by the use of
heat-inactivated paraprobiotic bacteria (Taverniti & Guglielmetti, 2011).
Second, a longer shelf life is an advantage in the use of paraprobiotics
(Adams, 2010). In developing areas, infrastructure developments in
chilled food delivery systems and domestic refrigeration circumstances
have been delayed and remain insufﬁcient. As foods containing
paraprobiotics do not need to be kept at a low temperature for storage,
this characteristic constitutes a major beneﬁt. Even in developed areas,
conveying chilled food products containing live LAB presents difﬁculties.
There has been no report on the intestinal regulatory activity of
heat-inactivated rod-shaped LAB, though beverages based on heat-
inactivated FM containing LAB are commercially available. In this
study, we ﬁrst examined the intestinal regulatory effect of a heat-
inactivated CP2305 strain that was isolated from human feces. The
effect of heat-inactivated LAB cells on the regulation of intestinal
function is not well understood, especially for rod-shaped LAB. To
evaluate the effect of heat-inactivated CP2305 on intestinal function,
we designed a double-blind randomized controlled trial.Table 2
Constituents of the beverages.
Constituent (w/w%) Placebo beverage Test beverage
CP2305-fermented milk 0.000 13.950
Skimmed milk powder 0.698 0.000
Yeast extract powder 0.017 0.000
Granulated sugar powder 8.000 8.000
50% lactate 0.683 0.532
Stabilizer 0.140 0.140
Pectin powder 0.080 0.080
Sodium citrate 0.160 0.160
Yogurt ﬂavor 0.100 0.100
Water 90.120 84.016
Total 100.000 100.0002. Materials and methods
2.1. Subjects
All of these procedures were approved by the research ethics
committees of Calpis Co., Ltd. (No. 13S51), and Utsukushigaoka
Hospital. The trial was conducted in accordance with the Declaration
of Helsinki. All subjects provided written informed consent before
inclusion in the study.
Volunteers (n= 40) were recruited among healthy individuals with
a tendency toward constipation (bowelmovements b4 times perweek)
or frequent bowel movements (≥10 times per week) in Japan. Subjects(n= 39)who completed the studywere of both genders (15males and
24 females) andwere 20–70 years of age (Table 1). Subjects were divid-
ed into the placebo (n = 20) and CP2305 groups (n = 19).2.2. FM preparation
Two types of beverages were prepared: a beverage containing heat-
inactivated CP2305-fermented milk and a placebo beverage. The
constituents of the beverages are shown in Table 2. The test beverage
was made of heat-treated CP2305 FM containing CP2305 (10% (w/w)
skimmed milk +0.25% (w/w) yeast extract). The placebo beverage
was made of a bacteria-free, artiﬁcially sour milk-base corresponding
to the test beverage. It was prepared by ﬂavoring, sweetening with
granulated sugar and acidiﬁcation with lactic acid. The test and placebo
beverages were similar in ﬂavor, appearance, color tone, texture and
taste and were thus indistinguishable by organoleptic examination by
test panels. The CP2305 FMwas sterilized at 69 °C for over 1 s to termi-
nate themetabolic activity. After preparation of theﬁnalmixture for test
beverages, including intermediate materials and the FM, ﬁnal steriliza-
tion was performed with a continuous sterilizer at 95 °C for 30 s. No liv-
ing bacteria were detected in either the CP2305 FM-containing
beverage or the placebo beverage. Bacterial checks were carried out as
follows. The beverages were cultured on BCP plate count agar and
MRS agar for detecting viable CP2305 at 37 °C for 48 h under partial aer-
obic conditions (5–8%CO2, 6–12%O2), EG blood agar for detecting viable
anaerobic bacteria under anaerobic conditions (20% CO2 in air) at 37 °C
for 48 h and StandardMethod agar for cultivating aerobes.We found no
bacterial colonies on the plates after the culture. Both beverages were
packed in 190-g (daily intake dosage) doses andwere served to the sub-
jects. The CP2305-containing test beverage contained 1 × 1010 bacterial
cells per container. The bacterial counts were conﬁrmed by culturing
CP2305 FM just after preparation and performing direct counts using a
bacterial counting chamber and a Coulter counter after the clotted
milk proteins in the FM were dissolved by adding sodium hydroxide.
These products were prepared only for the study and were provided
by Calpis Co., Ltd. (Tokyo, Japan).
Fig. 1. Changes in objective BSS scores after 3 weeks of administration. The solid line is the regression line, and the dotted line gives the bounds for 95% conﬁdence. (A) Changes in the
CP2305 group: R2 = 0.7761, p b 0.0001. (B) Changes in the placebo group: R2 = 0.1110, p = 0.1513. Objective BSS scores were measured in fecal samples that were collected at end
of the observation period and the end of the ingestion period everyweek, anddifferences between thebaseline and after 3weekswere calculated. In theCP2305-treated subjects, objective
BSS scores were changed signiﬁcantly after 3 weeks of ingestion.
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The study was a randomized, double-blind, placebo-controlled trial.
After medical screening, the observation period was set for 2 weeks.
Thereafter, subjects were randomized to drink a container of the
assigned beverage every day for 3 weeks. A 2-week follow-up period
followed. A total of four visits were scheduled during the study period.
Subjects were instructed to not change their eating and ﬁtness habits
throughout the entire study period. During the 7 weeks of the study,
subjects kept a stool diary to record the frequency of bowelmovements,
the feeling after defecation and the fecal conditions (form, color tone,
volume of output and odor intensity). The feeling after defecation was
scored between 1 (refreshed) to 4 (discomfort). Fecal form and color
were evaluated in accordance with the Bristol stool scale (BSS; Lewis
& Heaton, 1997) and the fecal color chart, which was scored between
1 (dark brown) and 7 (yellow). The BSS scores recorded in the subjects'
diaries were treated as subjective BSS scores. Fecal samples wereFig. 2. Changes in subjective BSS scores and indefecation habits and stool characteristics. Subject
subjects. The horizontal axis represents time, and the vertical axis represents the amount of cha
The stool form typewas closer to the ideal condition after CP2305 ingestion. Defecation habits a
subjects. The feeling after defecationwas scored between1 (refreshed) and 4 (discomfort) andw
improved.collected three times: at the ends of the observation, ingestion and
follow-up periods. These samples were evaluated objectively using the
BSS (objective BSS scores), and we analyzed the putrefactive products,
the microbial metabolites and the composition of the intestinal
microbiota.
2.4. Analyses of putrefactive products and SCFAs in fecal samples
Fecal metabolites, including decomposed putrefactive products and
short-chain fatty acids (SCFAs; tartaric acid, malic acid, succinic acid,
lactic acid, formic acid, acetic acid, propionic acid, isobutyric acid, butyr-
ic acid, isovaleric acid and valeric acid) were analyzed using the
methods described by Ikeda et al. (1994). The putrefactive products, in-
cluding phenol, 4-ethylphenol, p-cresol, indole and skatole, in the fecal
samples were determined by gas–liquid chromatography using a GC-
2014 ﬁtted with a ﬂame ionization detector (Shimadzu, Kyoto, Japan).
A glass-lined columnwas packed with Silicon GE SE-30 on Chromosorbive BSS: (A) all subjects, (B) rigid-type subjects, (C) soft-type subjects and (D) normal-type
nge between the average at baseline and the average at everyweek of the ingestion period.
nd stool characteristics: (E) rigid-type subjects, (F) soft-type subjects and (G) normal-type
asmeasured after defecation until the end of the ingestion period. In all types, scoreswere
Fig. 3. Changes in defecation habits and stool characteristics. (A) Stool output was in-
creased in the CP2305 group. (B) Color tone became lighter in the CP2305 group. Color
tone was scored between 1 (dark brown) and 7 (yellow). (C) Odor score and (D) the fre-
quency of fecal movement did not change.
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at 140 °C (column) and 200 °C (inlet and detector). SCFAs were ana-
lyzed by high-performance liquid chromatography (HPLC)with a pH in-
dicator (LaChrom Elite; Hitachi High-Technologies Corporation, Tokyo,
Japan). The column (RSpak KC-811 column; Showa Denko K. K.,
Tokyo, Japan) was operated at 45 °C, the eluent was 3 mmol L−1
perchloric acid, and the ﬂow rate was 1.0 mL min−1. Each of the
SCFAs was measured separately.
2.5. Analysis of intestinal microbiota
The intestinal microbiota were generally analyzed using
terminal-restriction fragment length polymorphism (T-RFLP) anal-
ysis (Nagashima, Hisada, Sato, & Mochizuki, 2003) at TechnoSuruga
Laboratory Co., Ltd. (Shizuoka, Japan). Using ﬂuorescent-labeled
primers, the 16S rRNA gene was ampliﬁed from the DNA of fecal
samples. The ampliﬁed products were digested with a restriction
enzyme (Bsl I) and classiﬁed by their distribution of operationalFig. 4. Concentrations of SCFAs in fecal samples. Open circles indicate the placebo group, and clos
dotted line is that of the placebo.(A) Propionic acidR2 = 0.4899, p = 0.0904Slope = −0.91
0.0343Slope=−1.0901, Y intercept= 1.0014 (placebo), 1.1724 (CP2305)(C) Valeric acidR2 =taxonomic units. Further identiﬁcation of the bacterial species was
performed by cloning and sequencing if needed. Thereafter, quanti-
tative PCR procedures targeting each speciﬁc bacterial group or
species were applied to analyze the details of each bacterial group.
2.6. Statistical analysis
All statistical analyses were performed using JMP11 Pro (SAS Insti-
tute, Cary, NC, USA). Subjects were classiﬁed into three types by the ob-
jective BSS scores at a set point: rigid-type (BSS 1–3), normal-type (BSS
4) and soft-type (BSS 5–7). An analysis of covariance (ANCOVA) was
used to analyze the data of the cases if the initial values seemed mean-
ingful and operative. Regression analysis was employed to calculate the
coefﬁcient of determination and to estimate the intercept and slope
with their signiﬁcant probabilities on a group basis. Otherwise, an anal-
ysis of variance (ANOVA) was applied to analyze the differences
between the means of the two groups with repeated measures. The re-
sults are expressed as the means ± standard errors (SEM). Differences
less than 0.05 were considered signiﬁcant. Student's t-test was applied
to compare the mean values of the placebo and test groups at each
time point.
3. Results
Forty volunteers were enrolled, and thirty-nine subjects completed
the study. Table 1 shows the baseline characteristics of the subjects.
No adverse events were observed throughout the trial. Subjects were
classiﬁed into three types based on objective BSS scores: 11 rigid-type
subjects (BSS 1–3), 8 normal-type subjects (BSS 4) and 20 soft-type sub-
jects (BSS 5–7).
The objective BSS scores of the CP2305-treated subjects changed sig-
niﬁcantly after 3 weeks of ingestion (Fig. 1). The objective BSS scores of
the CP2305-treated rigid-type subjects increased signiﬁcantly (p b
0.05), indicating that the consistency of their stools became softer and
smoother (Fig. 1A). In contrast, the objective BSS scores of the
CP2305-treated soft-type subjects decreased due to harder and more
solid consistencies. Fig. 2A–D shows the results of the time-dependent
changes in subjective BSS scores, which indicated almost the same
trend as in the results for the objective BSS scores. Hence, the stool
form types were closer to the ideal condition after ingestion of the
CP2305 beverage for both rigid- and soft-type subjects.
The ability of the beverage to improve the feeling of “refreshment”
after bowel movements was evaluated using subjective scores
(Fig. 2E–G). The feeling after defecation was scored between 1
(refreshed) and 4 (discomfort). In the CP2305 group, the scores were
lower than those in the placebo group both during and after treatment.
The scores were lower for the CP2305-treated rigid-type subjects
(Fig. 2E) than for the soft-type subjects (Fig. 2G). Fig. 3 shows the chang-
es in fecal characteristics, including the output, color tone and odor
intensity, recorded by the subjects. In the CP2305 group, the stooled circles indicate the CP2305 group. The solid line is the regression line of CP2305, and the
70, Y intercept = 1.1572 (placebo), 1.3000 (CP2305)(B) Butyric acidR2 = 0.4550, p =
0.4220, p = 0.0400Slope =−0.6500, Y intercept = 0.1081 (placebo), 0.1507 (CP2305).
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and the fecal color tone (Fig. 3B) became lighter (p b 0.05). No signif-
icant differences in fecal odor scores (Fig. 3C) and the frequency of
stool output (Fig. 3D) were identiﬁed between the CP2305 and pla-
cebo groups.
In the analyses of metabolites in stools, the concentrations of SCFAs
(i.e., propionic acid, butyric acid and valeric acid) were signiﬁcantly in-
creased in the CP2305 group (Fig. 4). In contrast, there were no signiﬁ-
cant differences in the fecal concentrations of putrefactive products
between the CP2305 and placebo groups.Fig. 5. Components of the intestinal microbiota in fecal samples. Column charts (100% stacke
subjects.Fig. 5 shows the results for the analysis of the intestinalmicrobiota in
the fecal samples. The population of the bacterial group of Clostridium
cluster IV was signiﬁcantly increased in the CP2305 group (Fig. 6).
Changes in the log population of Faecalibacterium prausnitzii showed
an increasing tendency (p = 0.0714) in the CP2305 group.
4. Discussion
In this study, we described the effects of administering non-living
CP2305 as a paraprobiotic on intestinal function as judged by thed) of (A) all subjects, (B) rigid-type subjects, (C) soft-type subjects and (D) normal-type
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CP2305 FM and that of artiﬁcially acidiﬁedmilk. Live CP2305 as a probi-
otic is safe and showed regulatory effects on stool habits; i.e., daily fecal
output and frequency were increased in subjects who had a tendency
toward constipation (unpublished result). We note that even in this
case, a large proportion of the CP2305 population in the FM appeared
to be dead. Within a week of storage under refrigeration, non-living
CP2305 became dominant inside the test beverage. However, the bene-
ﬁcial effects of a completely sterilized bacterial preparation had not pre-
viously been examined. To evaluate the effects of heat-inactivated
CP2305 bacterial cells, we conducted a trial using a beverage based on
heat-inactivated CP2305 FM, with milk artiﬁcially acidiﬁed with lactate
as the placebo.
We found that the ingestion of the beverage containing heat-
inactivated CP2305 FM signiﬁcantly improved stool habits and fecal
characteristics, including objective and subjective BSS scores (Figs. 1
and 2), stool output and color tone (Fig. 3A and B). Following intake of
the heat-inactivated CP2305 FM-containing beverage, the stool charac-
teristics of the volunteers were close to the ideal condition. Fig. 1 shows
the objective BSS scores of the CP2305 group, which were improved in
all subjects. The stool characteristics were closer to ideal (BSS score
4) for original conditions of both soft-type (BSS scores 5–7) and rigid-
type (BSS scores 1–3) stools.
The analysis of subjective scores also suggested similar improve-
ment effects on the fecal characteristics. The subjective BSS scores
were improved in the CP2305 group, especially for the rigid-type sub-
jects (Fig. 2A–D). These ﬁndings suggested that the consumption of
heat-inactivated CP2305 resulted in improvements in bowel move-
ments. Improvements were also observed in stool output and fecal
color tone (Fig. 3B). These results demonstrated that administration of
heat-inactivated CP2305 led to improvements in defecation and stool
characteristics, whichmay be related to the improvement in the feeling
after defecation in the rigid-type subjects (Fig. 2E). In the CP2305 group,
subjects felt refreshed after defecation. This effect was also typical for
the rigid-type subjects (Fig. 2E). The improvements in stool habits and
fecal characteristics correlated with answers on the questionnaireFig. 6.Changes in Clostridium cluster IV in the fecal samples. (A) All subjects, (B) rigid-type
subjects, (C) soft-type subjects and (D) normal-type subjects. Changes in the component
ratio (%) of Clostridium cluster IV in the fecal samples.indicating that heat-inactivated CP2305 provided them with a good
feeling after defecationwith altered bowel habits during and after its in-
gestion. In contrast, the fecal odor score and the amounts of putrefactive
products in feces were unchanged. These ﬁndings may be related to the
relatively small number of volunteers employed in this study, as the lack
of signiﬁcance might be due to the limited statistical power of the trial.
Meanwhile, the mechanisms underlying the improved regulation of
intestinal function remain unclear. The effects were probably caused by
improvement of the intestinal environment through the administration
of the heat-inactivated CP2305 FM-containing beverage. A possible key
ingredientwith a role in the improvement observed in the test beverage
condition may be the sterilized bacterial cells themselves. The test bev-
erage included approximately 1 × 1010 cells. The presence of these cells,
which is themain difference between the active and placebo beverages,
likely plays a key role; however, otherminor possible candidates remain
to be assessed. Further studies are needed to clarify the active mate-
rial(s). Thus, we need to evaluate the effects of the heat-inactivated
CP2305 cells themselves using volunteers and animals. Possible candi-
dates are minor metabolites, other than lactate, that are produced by
the bacterium, such as gassericins, which are produced by LAB
(Dobson, Cotter, Ross, & Hill, 2012; Pandey, Malik, Kaushik, & Singroha,
2013). However, it has been reported that the productivity of
gassericins in milk-based media is generally poor (Arakawa, Kawai,
Nishimura, Kitazawa, & Saito, 2009). The acting material(s) and their
mode(s) of action need to be determined to elucidate the exact mecha-
nisms of action of the heat-inactivated CP2305 FM. Here, we analyzed
changes in the composition of the microbiota, the contents of fecal
SCFAs and fecal putrefactive products. We believe that these analyses
are helpful and that they may provide key information for identifying
the mode of action.
The analyses indicated that heat-inactivated CP2305 favorably inﬂu-
ences the intestinal environment. The composition of microbiota was
changed only in the CP2305 group (Fig. 5). In particular, the Clostridium
cluster IV group, which includes F. prausnitzii, was increased substan-
tially in the heat-inactivated CP2305 group (Fig. 6), and the population
of F. prausnitzii showed an increasing trend (data not shown: p =
0.0714).Meanwhile, the concentrations of SCFAswere increased during
ingestion of heat-inactivated CP2305, including signiﬁcant increases in
propionic acid, butyric acid and valeric acid (Fig. 4). Many bacteria be-
longing to Clostridium cluster IV are well known as SCFA producers
(Louis, Scott, Duncan, & Flint, 2007), but we were unable to determine
the relationships between these ﬁndings. Heat-inactivated CP2305
may have a beneﬁcial inﬂuence on the intestine and the intestinal envi-
ronment through stimulation by SCFAs produced by internal members
of the pre-existing intestinal microbiota. However, it is not clearwheth-
er heat-inactivated CP2305 FM stimulates the proliferation of some bac-
terial groups that produce high levels of SCFAs or activates their
metabolism without changes in their numbers or whether these two
effects occur in parallel.
We focused on the possible advantages of the mechanism by
which CP2305 acts as a paraprobiotic. Bacterial components of
heat-inactivated CP2305 cells may act directly on intestine via an
unknown mechanism to induce the desirable host's biological re-
sponsiveness. Oral administration of the living form of the bacterial
strain leads to establishment in the gut system. Ten months after
three ingestions of FM including 1 × 1011 live cells, 4 of 11 volun-
teers still carried it in their gut systems (unpublished results). This
fact indicated that CP2305 has a strong afﬁnity for the intestinal surfaces
of some volunteers and is retained inside the gut system thereafter, po-
tentially for long periods of time.We believe that this phenomenonmay
be an important aspect of the paraprobiotic mechanism. Several studies
have suggested the presence of a relationship between stool abnormal-
ities, such as irritable bowel syndrome, and the intestinalmicrobiota via
the brain–gut axis pathway (Coss-Adame & Rao, 2014), suggesting a
brain–gut interaction. In that study, the intestinalmicrobiota inﬂuenced
the host brain function through the vagus nerve. The functional changes
39D. Sawada et al. / Food Research International 79 (2016) 33–39may affect the functions of the whole body, including the gut itself
(Derrien & van Hylckama Vlieg, 2015; Dinan, Stilling, Stanton, &
Cryan, 2015; Kim et al., 2014; Sampson & Mazmanian, 2015). Changes
in the composition of the microbiota may also be reﬂected by changes
in host functions through brain–gut interactions triggered by the
signal(s) originating from CP2305 ingestion.
We found that the heat-inactivated CP2305 FM-containing beverage
had a positive effect on the regulation of intestinal function. Admin-
istration of the heat-inactivated CP2305 FM-containing beverage led
to signiﬁcant improvements in stool characteristics, the intestinal
environment and the feeling after defecation. These effects were par-
ticularly observed in subjects with a tendency toward constipation.
The results suggest that heat-treated CP2305 has beneﬁcial effects
on digestive tract function even when heat-inactivated. These ﬁnd-
ings may suggest that this strain has the potential for application as
a paraprobiotic in the food industry. However, the exact mode of action
of heat-inactivated CP2305 FM remains unclear. Further studies are
required to identify the key factor(s) and the functional mechanisms.
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